Surveillance and outbreak report Open Access
Like 0


In February and March 2016, four cases of serogroup B invasive meningococcal disease (IMD) occurred over 3 weeks in a small area north of Lyon in the Auvergne-Rhône-Alpes region, France. There were no deaths but two cases had sequelae. This community outbreak was caused by a rare meningococcal strain of the clonal complex ST-32, covered by the 4CMenB/Bexsero vaccine. The incidence rate for serogroup B IMD in this area was 22.5 per 100,000 inhabitants, which is above the epidemic threshold (10/100,000). The number of cases observed was significantly higher than expected in the age group of 0–24 year-olds (standardised incidence ratio: 96). These results suggested the potential emergence of this invasive strain in this sub-population. In accordance with French recommendations, it was decided to vaccinate the population aged between 2 months and 24 years, living, working or studying in the epidemic area. The vaccination campaign took place from April to September 2016. Vaccination coverage was estimated at 47% for one dose and 40% for two doses. The lowest coverage estimations were observed for the age groups younger than 3 and 15–19 years. Enhanced epidemiological and microbiological surveillance reported a fifth case in June 2016, outside the epidemic area.


Article metrics loading...

Loading full text...

Full text loading...



  1. Santé publique France. Bilans annuels. Les infections invasives à méningocoques en 2015. [Annual reports: invasive meningococcal infections in 2015]. Paris: Santé publique France. [Accessed: March 2017]. French. Available from: http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Infections-invasives-a-meningocoques/Donnees-epidemiologiques
  2. French Ministry of Social Affairs and Health. Instruction DGS/RI1/DUS/2014/301 du 24 octobre 2014 relative à la prophylaxie des infections invasives à méningocoque. [National recommendations and policy regarding prophylaxis of invasive meningococcal diseases; DGS/RI1/DUS/2014/301, 24 October 2014]. Paris: French Ministry of Social Affairs and Health; 2014. French. Available from: http://social-sante.gouv.fr/IMG/pdf/cir_38936.pdf
  3. Perrocheau A. Outbreak of group B meningococcal disease in France prompted community chemoprophylaxis. Euro Surveill. 2000;4(13):1631. Available from: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=1631
  4. Caron F, du Châtelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455-63.  https://doi.org/10.1016/S1473-3099(11)70027-5  PMID: 21489881 
  5. Delisle E, Larrieu S, Simões J, Laylle N, De Pommerol M, Taha MK, et al. Community outbreak of group B meningococcal disease in southwest France--December 2008 to September 2009. Euro Surveill. 2010;15(37):19665. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19665 PMID: 20929645 
  6. Santé publique France. Calendrier des vaccinations et recommandations vaccinales 2016. [Vaccination schedule and vaccine recommendations 2016]. Bulletin épidémiologique hebdomadaire. Hors-série; 20 Apr 2016. French. Available from: http://invs.santepubliquefrance.fr/fr./Publications-et-outils/BEH-Bulletin-epidemiologique-hebdomadaire/Archives/2016/BEH-hors-serie-Calendrier-des-vaccinations-et-recommandations-vaccinales-2016
  7. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA. 1998;95(6):3140-5.  https://doi.org/10.1073/pnas.95.6.3140  PMID: 9501229 
  8. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416-25.  https://doi.org/10.1016/S1473-3099(13)70006-9  PMID: 23414709 
  9. Hong E, Terrade A, Taha MK. Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine. Hum Vaccin Immunother. 2017;13(3):645-8.  https://doi.org/10.1080/21645515.2016.1241358  PMID: 27808594 
  10. Parent du Chatelet I, Deghmane AE, Antona D, Hong E, Fonteneau L, Taha MK, et al. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015. J Infect. 2017;74(6):564-74.  https://doi.org/10.1016/j.jinf.2017.02.011  PMID: 28279715 
  11. Hill DM, Lucidarme J, Gray SJ, Newbold LS, Ure R, Brehony C, et al. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Lancet Infect Dis. 2015;15(12):1420-8.  https://doi.org/10.1016/S1473-3099(15)00267-4  PMID: 26515523 
  12. Haut conseil de la santé Publique. Avis relatif à l'utilisation du vaccin Bexsero. [Opinion on the use of the Bexsero vaccine]. Paris: Haut conseil de la santé Publique; 25 Oct 2013. French. Available from: https://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20131025_vaccmeningocoqueBBexsero.pdf
  13. Watson PS, Turner DP. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. Vaccine. 2016;34(7):875-80.  https://doi.org/10.1016/j.vaccine.2015.11.057  PMID: 26686570 
  14. Botrel MA, Fonteneau L, Boussac-Zarebska M, Parent du Chatelet I, Guthmann JP, Levy-Bruhl D. Estimation des couvertures vaccinales à partir des données de l’Assurance maladie. Exemple de la vaccination contre le meningocoque C. [Estimated vaccine coverage based on health insurance data. Example of vaccination against meningococcus C]. Paris: Santé publique France. 2015; French. Available from: http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2015/Estimation-des-couvertures-vaccinales-a-partir-des-donnees-de-l-Assurance-maladie
  15. Institut de veille sanitaire. Etude de la couverture vaccinale lors de la campagne de vaccination préventive contre le méningocoque C, Puy de Dôme, 2002. [Analysis of vaccine coverage during a preventive vaccination campaign against meningococcus C, Puy de Dôme, 2002]. Saint-Maurice: Institut de veille sanitaire; 2002. French. Available from: http://opac.invs.sante.fr/doc_num.php?explnum_id=5597
  16. Institut de veille sanitaire. Etude de la couverture vaccinale suite à la campagne de vaccination contre le méningocoque C dans les Landes, les Pyrénées Atlantiques et les Hautes Pyrénées en 2002. [Analysis of vaccine coverage following a preventive vaccination campaign against meningococcus C, Landes, Pyrénées Atlantiques and Hautes Pyrénées in 2002]. Saint-Maurice: Institut de veille sanitaire; 2004. French. Available from: http://opac.invs.sante.fr/doc_num.php?explnum_id=5758
  17. Renaudat C, Aboukaïs S, Grenier-Tisserand P, Armengaud A, Franke F, Six C, et al. Évaluation des couvertures vaccinales et des campagnes de vaccination contre le méningocoque C dans la vallée de Barcelonnette, Alpes de Haute-Provence, janvier-février 2007. [Evaluation of the vaccination coverage and the vaccination campaigns against meningococcus C in Barcelonnette, Alpes de Haute-Provence, January to February 2007]. Saint-Maurice: Institut de veille sanitaire; 2012. French. Available from: http://opac.invs.sante.fr/doc_num.php?explnum_id=8760

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error